Cubist Systematic Strategies LLC Sells 3,149 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Cubist Systematic Strategies LLC reduced its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 13.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 20,976 shares of the company’s stock after selling 3,149 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Dianthus Therapeutics were worth $543,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $112,000. American Century Companies Inc. lifted its position in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after buying an additional 8,473 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $236,000. WINTON GROUP Ltd bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $265,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $334,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on DNTH shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Oppenheimer initiated coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 target price for the company. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an “overweight” rating for the company. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Finally, Robert W. Baird initiated coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price target for the company. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $45.13.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $27.50 on Friday. The business has a 50 day simple moving average of $27.77 and a 200 day simple moving average of $26.15. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77. The stock has a market capitalization of $807.68 million, a P/E ratio of -4.96 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.